Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex), in Participants With RMS to Evaluate Efficacy and Safety

Next Previous
Trial Profile

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex), in Participants With RMS to Evaluate Efficacy and Safety

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evobrutinib (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLUTION RMS2
  • Sponsors EMD Serono Research & Development Institute; Merck KGaA

Most Recent Events

  • 28 May 2020 Status changed from recruiting to discontinued.
  • 30 Mar 2020 this trial has been discontinued in Bulgaria as per European Clinical Trials Database
  • 10 Sep 2019 According to a Merck & Co media release, enrollment is expected to complete in June 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top